Pinoy co-founded healthcare startup Intervenn opens office in Pasig City amid expansion plans in PH
InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, has recently opened an office in Ortigas Center, Pasig City in line with its goal to expand its global presence.
“Our global expansion reflects the significant opportunity to apply glycoproteomics to improve clinical decision-making and translational research on a worldwide scale,” InterVenn Biosciences CEO Aldo Carrascoso said. “Our new offices and laboratory space will enable us to scale our operations, better connect with biomedical hubs, access local talent and serve different regions with localized resources.”
InterVenn is headquartered in San Francisco, California, U.S.A., but with half of the company’s global workers residing in the Philippines, which includes one of its founders, Carrascoso, the company sees opening a hub in Manila as an opportunity to leverage the available talent in the country.
“InterVenn has made significant progress in early cancer detection thanks to the brilliant and dedicated Filipino engineers we have on board,” Carrascoso added. “They help build and maintain the front end, back end, and cloud infrastructure of our next-generation liquid biopsy, as we all work together to reach a world where no one should ever be blindsided by disease.”
“One hundred percent of our software is proudly Philippine-made. We started this venture with the goal of not just having the means of finding a cure and early detection of cancer, but to also showcase to everyone that we Filipinos can achieve this on a global scale,” InterVenn Philippines general manager Axel Kornerup revealed.
The startup also sees this as a way to help provide more job opportunities to Filipino software developers.
Aside from the one in the Philippines, the company also opened state-of-the-art laboratories and office spaces in multiple new locations in Asia-Pacific and North America, namely in Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California.
The company’s expansion scales up its software development, technical support, clinical research, and business development.
Co-founded by Stanford professor Dr. Carolyn Bertozzi, University of California-Davis professor Dr. Carlito LeBrilla, and AI/ML and blockchain expert Carrascoso, InterVenn is the company behind the world’s first AI-enabled software platform that can perform glycoproteomic analysis and can work on a variety of mass spectrometry instruments to create high-throughput, automated analysis solutions for both research and clinical applications. Its goal is to help accelerate the shift from the healthcare industry’s traditional focus on disease management to the new realm of preventive care and health management.
It recently disclosed that it raised $201 million in a Series C funding round in 2021, which brings its total funding to over P13 billion since it was founded in 2017.
Sources:
SUGGESTED ARTICLES
